Oppenheimer & Co’s ANI Pharmaceuticals ANIP Stock Holding History

Oppenheimer & Co’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,225	Closed	-$236K	–	1272
2016 Q2	$236K	Sell	4,225 -3,023	-42%	-$147K	0.01%	1041
2016 Q1	$244K	Sell	7,248 -2,636	-27%	-$89.4K	0.01%	1019
2015 Q4	$446K	Buy	+9,884	New	+$425K	0.01%	807
2015 Q3	–	Sell	-4,630	Closed	-$287K	–	1351
2015 Q2	$287K	Sell	4,630 -2,269	-33%	-$135K	0.01%	1108
2015 Q1	$431K	Sell	6,899 -328	-5%	-$20K	0.01%	941
2014 Q4	$407K	Buy	+7,227	New	+$319K	0.01%	904

Other funds holding ANIP

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Oppenheimer & Co's ANIP Position: Q3 2016 in Review

Oppenheimer & Co sold out of ANI Pharmaceuticals (ANIP) in Q3 2016, closing a stake of 4,225 shares — an estimated $236K sold.

Oppenheimer & Co first reported a position in ANIP in Q4 2014 and held it in 6 quarters. The position peaked at $446K in Q4 2015. 171 funds tracked by Wall St. Rank hold ANIP as of Q3 2016.

Oppenheimer & Co reported no remaining ANI Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Oppenheimer & Co sold 4,225 ANI Pharmaceuticals shares in Q3 2016, an estimated $236K.
Oppenheimer & Co first reported a position in ANI Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Oppenheimer & Co's ANI Pharmaceuticals position peaked at $446K in Q4 2015.
171 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2016.

Based on Oppenheimer & Co's 13F filing for Q3 2016, filed 7 Nov 2016.